Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


BOTOX approved for treatment of Overactive Bladder

BOTOX approved for treatment of Overactive Bladder

BOTOX® (botulinum toxin type A) injections registered for management of overactive bladder - Twice yearly treatment allows New Zealanders with bladder dysfunction to gain control1

Auckland / Wellington, New Zealand – A twice yearly treatment option, BOTOX® (botulinum toxin type A),1 is now available for more than 500,000 New Zealanders experiencing overactive bladder (OAB) - a chronic and debilitating condition,2,3 that at its worst can affect social lives, make people feel secluded and cause psychological stress.2

The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has registered BOTOX®(botulinum toxin type A), for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency and frequency, in adult patients who have an inadequate response to, or are intolerant of, an anticholinergic medication.1 This makes BOTOX® the first treatment option to help patients gain control of their bladder, with the effect lasting up to six months before re-treatment is required.1

The treatment of OAB with BOTOX® involves injecting 100U of BOTOX® into the detrusor muscle. This helps to relax and calm the bladder muscle, which minimises sudden contraction and reduces leakage episodes9commonly experienced with people suffering from OAB.1 It also targets the nerves that control the sensation of urgency,9 a common and bothersome symptom of OAB.4

This is not just a condition that strikes the elderly, OAB is also relatively common in young people - predominantly women - many of whom are unaware the condition can be treated.4 While the prevalence of OAB is a common condition affecting up to 17 per cent of the general population2,9, the prevalence of urinary incontinence is even higher in adult Maori women at approximately 50 per cent.5 For Maori women in particular, there are many factors including their social, cultural and economic conditions that influence their health and wellbeing including seeking and accessing affordable and appropriate health care.

According to Dr. Sharon English, Consultant Urologist, “Only a small proportion of people with overactive bladder seek health professional assistance. Many women I see are very embarrassed to even talk to a medical professional. People experiencing involuntary leakage of urine, a need to empty the bladder more than eight times a day and frequently experiencing an urgent ‘need to go’, regardless of actual need6 should ask their GPs to refer them to an urologist to discuss how best to treat their condition and explore treatment options.”

Oral anticholinergics are prescribed as first-line treatment for OAB, however approximately 50 per cent of patients do not persist with their oral treatment after the first prescription, over 70 per cent of patients stop taking anticholinergics within one year7 due to inadequate response or intolerance for these medications.3,7,8

Dr English adds: “Overactive bladder can be a difficult condition to treat with limited options for patients who have not had success with oral treatments. With the availability of a new treatment people with this potentially incapacitating condition now have another treatment option to consider in their quest for regaining a ‘normal’ life.”

Support and information is available from the New Zealand Continence Association please or call the Continence Help Line on 0800 650 659
For consumer medicine information about this treatment please see Further information about BOTOX® can also be found on


© Scoop Media

Business Headlines | Sci-Tech Headlines


Banks: Westpac Keeps Core Government Transactions Contract

The local arm of Westpac Banking Corp has kept its contract with the New Zealand government to provide core transactions, but will have to share peripheral services with its rivals. More>>


Science Investment Plan: Universities Welcome Statement

Universities New Zealand has welcomed the National Statement of Science Investment released by the Government today... this is a critical document as it sets out the Government’s ten-year strategic direction that will guide future investment in New Zealand’s science system. More>>


Scouring: Cavalier Merger Would Extract 'Monopoly Rents' - Godfrey Hirst

A merger of Cavalier Wool Holdings and New Zealand Wool Services International's two wool scouring operations would create a monopoly, says carpet maker Godfrey Hirst. The Commerce Commission on Friday released its second draft determination on the merger, maintaining its view that the public benefits would outweigh the loss of competition. More>>


Scoop Review Of Books: She Means Business

As Foreman says in her conclusion, this is a business book. It opens with a brief biographical section followed by a collection of interesting tips for entrepreneurs... More>>


Hourly Wage Gap Grows: Gender Pay Gap Still Fixed At Fourteen Percent

“The totally unchanged pay gap is a slap in the face for women, families and the economy,” says Coalition spokesperson, Angela McLeod. Even worse, Māori and Pacific women face an outrageous pay gap of 28% and 33% when compared with the pay packets of Pākehā men. More>>


Housing: English On Housing Affordability And The Economy

"Long lead times in the planning process tend to drive prices higher in the upswing of the housing cycle. And those lead times increase the risk that eight years later, when additional supply arrives, the demand shock that spurred the additional supply has reversed. The resulting excess supply could produce a price crash..." More>>


Get More From Scoop

Search Scoop  
Powered by Vodafone
NZ independent news